Results 101 to 110 of about 40,015 (285)

Frequency of Bacterial Agents Isolated From Patients With Chronic Sinusitis in Northern Iran

open access: hybrid, 2015
Rostam Pourmousa   +3 more
openalex   +2 more sources

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow   +3 more
wiley   +1 more source

Surgical Drainage and Simultaneous Sinus Floor Augmentation in Patients with Chronic Maxillary Sinusitis

open access: yesMedicina
Chronic maxillary sinusitis accompanied by severe thickening of the sinus mucosa, blockage of the ostium, and patient-reported symptoms requires preoperative assessment and treatment by an otolaryngologist before maxillary sinus floor augmentation (MSFA).
Won-Bae Park   +3 more
doaj   +1 more source

A relação entre doença do refluxo gastroesofágico e sinusite crônica/ The relationship between gastroesophageal reflux disease and chronic sinusitis [PDF]

open access: diamond, 2021
Virgínia Braz da Silva Vaz   +7 more
openalex   +1 more source

Evaluation of the performance of ChatGPT‐4 and ChatGPT‐4o as a learning tool in endodontics

open access: yesInternational Endodontic Journal, EarlyView.
Abstract Aims The aim of this study was to evaluate the accuracy and consistency of responses given by two different versions of Chat Generative Pre‐trained Transformer (ChatGPT), ChatGPT‐4, and ChatGPT‐4o, to multiple‐choice questions prepared from undergraduate endodontic education topics at different times of the day and on different days ...
Esra Arılı Öztürk   +2 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Bone lesions, chronic sinusitis, and perirenal involvement. [PDF]

open access: yesEJHaem, 2023
Suárez EU   +2 more
europepmc   +1 more source

Diagnostic dilemma in a case of chronic invasive fungal sinusitis solved using a novel diagnostic test

open access: diamond, 2021
Malavika Suresh   +6 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy